PDF(Sci-hub)
Abstract：
OBJECTIVE: To investigate the clinical effects of MUC1 on papillary thyroid cancer (PTC) and explore the relationship between MUC1 expression and BRAF mutation.
METHODS: The data of 69 patients subjected to fine-needle aspiration biopsy in our hospital and 486 patient data downloaded from The Cancer Genome Atlas (TCGA) database were used. Univariate and multivariate analyses were performed.
RESULTS: The results on the 486 patients recorded in the TCGA indicated that high MUC1 expression was independently related to BRAF mutation, lymph node metastasis (LNM), and unifocal type. In the 69 fine-needle aspiration biopsy patients with PTC, high MUC1 expression was significantly related to LNM and extrathyroid extension (ETE). The result of Pearson\'s correlation coefficient showed that BRAF mutation and MUC1 expression were moderately correlated. Moreover, in the subgroup with low MUC1 expression, the patients with BRAF mutation had higher ETE frequency and LNM than those without BRAF mutation. In the subgroup with BRAF mutation, patients with high MUC1 expression exhibited higher ETE frequency than those with low MUC1 expression, and high MUC1 expression occurred in older patients. In the subgroup with BRAF wild-type mutation, patients with high MUC1 expression had a higher incidence of ETE and LNM than those with low expression.
CONCLUSIONS: We demonstrated that the MUC1 is an important oncogene in PTC and may have great significance on therapeutic cancer vaccine development.
METHODS: The data of 69 patients subjected to fine-needle aspiration biopsy in our hospital and 486 patient data downloaded from The Cancer Genome Atlas (TCGA) database were used. Univariate and multivariate analyses were performed.
RESULTS: The results on the 486 patients recorded in the TCGA indicated that high MUC1 expression was independently related to BRAF mutation, lymph node metastasis (LNM), and unifocal type. In the 69 fine-needle aspiration biopsy patients with PTC, high MUC1 expression was significantly related to LNM and extrathyroid extension (ETE). The result of Pearson\'s correlation coefficient showed that BRAF mutation and MUC1 expression were moderately correlated. Moreover, in the subgroup with low MUC1 expression, the patients with BRAF mutation had higher ETE frequency and LNM than those without BRAF mutation. In the subgroup with BRAF mutation, patients with high MUC1 expression exhibited higher ETE frequency than those with low MUC1 expression, and high MUC1 expression occurred in older patients. In the subgroup with BRAF wild-type mutation, patients with high MUC1 expression had a higher incidence of ETE and LNM than those with low expression.
CONCLUSIONS: We demonstrated that the MUC1 is an important oncogene in PTC and may have great significance on therapeutic cancer vaccine development.
摘要：
目的：观察MUC1对甲状腺乳头状癌（PTC）的临床疗效，并探讨MUC1表达与BRAF突变的关系。
方法：使用在我院接受细针穿刺活检的69例患者的数据和从癌症基因组图谱（TCGA）数据库下载的486例患者数据。进行单变量和多变量分析。
结果：TCGA中记录的486例患者的结果表明，MUC1的高表达与BRAF突变独立相关，淋巴结转移（LNM），和单一类型。在69例PTC细针穿刺活检患者中，MUC1的高表达与LNM和甲状腺外延伸（ETE）显着相关。Pearson相关系数结果显示，BRAF突变与MUC1表达呈中度相关。此外，在MUC1低表达的亚组中，有BRAF突变的患者的ETE频率和LNM高于无BRAF突变的患者.在具有BRAF突变的亚组中，MUC1高表达的患者比MUC1低表达的患者表现出更高的ETE频率，MUC1高表达发生在老年患者中。在具有BRAF野生型突变的亚组中,MUC1高表达患者的ETE和LNM发生率高于低表达患者.
结论：我们证明MUC1是PTC中的重要癌基因，可能对治疗性癌症疫苗的开发具有重要意义。
方法：使用在我院接受细针穿刺活检的69例患者的数据和从癌症基因组图谱（TCGA）数据库下载的486例患者数据。进行单变量和多变量分析。
结果：TCGA中记录的486例患者的结果表明，MUC1的高表达与BRAF突变独立相关，淋巴结转移（LNM），和单一类型。在69例PTC细针穿刺活检患者中，MUC1的高表达与LNM和甲状腺外延伸（ETE）显着相关。Pearson相关系数结果显示，BRAF突变与MUC1表达呈中度相关。此外，在MUC1低表达的亚组中，有BRAF突变的患者的ETE频率和LNM高于无BRAF突变的患者.在具有BRAF突变的亚组中，MUC1高表达的患者比MUC1低表达的患者表现出更高的ETE频率，MUC1高表达发生在老年患者中。在具有BRAF野生型突变的亚组中,MUC1高表达患者的ETE和LNM发生率高于低表达患者.
结论：我们证明MUC1是PTC中的重要癌基因，可能对治疗性癌症疫苗的开发具有重要意义。
